» Articles » PMID: 34866034

Bloodstream Infection in Pediatric Patients with Febrile Neutropenia Induced by Chemotherapy

Overview
Specialty Hematology
Date 2021 Dec 6
PMID 34866034
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Febrile neutropenia (FN) is a serious complication of cancer chemotherapy. The present study aimed to identify risk factors for documented infection in pediatric patients with FN and cancer.

Methods: This prospective cohort study included patients under 18 years from 2016 to 2018. Infection was defined according to the Centers for Disease Control and Prevention criteria.

Results: A total of 172 febrile neutropenic episodes were evaluated. From univariate analysis, the risk factors were: female gender; monocyte count < 100 cell/mm³, platelets < 50,000, C-reactive protein (CRP) > 90 mg/dl and hemoglobin < 7mg/dl at the onset of an episode; two or more episodes of FN, and; fever onset; positive blood culture at the fever onset. Independent risk factors according to the multivariate analysis were: CRP at the onset of a febrile episode > 90mg/dl, fever onset and first blood culture with a positive result. The lowest probability of infection was related to first episode and to platelets > 50,000 at the onset of fever.

Conclusion: A CRP > 90 at the onset of a febrile episode, platelets < 50,000, second episode or more, first fever episode during hospitalization and positive first blood culture were found to be associated with a higher risk of infection and they could be useful for the establishment of risk scores for infection in neutropenic children.

Citing Articles

IL-6 and IL-10 Are Associated With Gram-Negative and Gram-Positive Bacteria Infection in Lymphoma.

Zhu Q, Li H, Zheng S, Wang B, Li M, Zeng W Front Immunol. 2022; 13:856039.

PMID: 35432366 PMC: 9011156. DOI: 10.3389/fimmu.2022.856039.

References
1.
Rondinelli P, Ribeiro K, de Camargo B . A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006; 28(10):665-70. DOI: 10.1097/01.mph.0000212996.94929.0b. View

2.
Ammann R, Bodmer N, Hirt A, Niggli F, Nadal D, Simon A . Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol. 2010; 28(12):2008-14. DOI: 10.1200/JCO.2009.25.8988. View

3.
Hakim H, Flynn P, Knapp K, Srivastava D, Gaur A . Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2009; 31(9):623-9. PMC: 2743072. DOI: 10.1097/MPH.0b013e3181b1edc6. View

4.
Kitanovski L, Jazbec J, Hojker S, Derganc M . Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Support Care Cancer. 2013; 22(1):269-77. DOI: 10.1007/s00520-013-1978-1. View

5.
Ammann R, Hirt A, Luthy A, Aebi C . Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol. 2003; 41(5):436-43. DOI: 10.1002/mpo.10320. View